Geneticists have a better understanding of how prehistoric pairings unfolded, with new research suggesting they were mostly ...

Q4 2025 earnings call highlights: 2026 revenue outlook, Bako/StrataDx deals, AI pathology gains, and customer-loss risks—read now.

As of Friday, February 27, Fulgent Genetics, Inc.’s FLGT share price has dipped by 31.34%, which has investors questioning if this is right time to buy.

Myriad Genetics (NASDAQ:MYGN) executives highlighted fourth quarter and full-year 2025 results alongside a slate of planned ...

Scientists have identified how specific genetic changes function in cells to influence disease risk and other human health ...

Opus Genetics targets inherited retinal diseases with one-dose AAV gene augmentations. Read why IRD stock is a Buy.

Myriad Genetics (MYGN) surged 24% in premarket trading on Tuesday after reporting a quarterly earnings beat and outlining a 2026 revenue target of $860 million to $880 million while highlighting ...

Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or ...

Duckweed is the fastest-growing flowering plant, but new knowledge of duckweed genetics discovered by Adelaide University researchers could lead to even faster growing rates. The research team, led by ...

Fulgent Genetics (NASDAQ:FLGT) used its fourth-quarter and full-year 2025 earnings call to outline continued growth in its laboratory services business, accelerating investments in digital pathology ...